Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat
Authors:
- 30 May 2015
- journal article
- review article
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 31 (5) , 572-588
Abstract
English-language literature cited in MEDLINE from January, 1980 to October 30, 2014 was searched by using terms of antipsychotic, generic and brand names of atypical antipsychotics, “bipolar depression/bipolar disorder”, “placebo”, and “trial”. The parameters of response (≥50% improvement on MADRS, Montgomery-Asberg Depression Rating Scale total score), remission (either ≤12 or 8 on MADRS total score at endpoint), discontinuation due to adverse events (DAEs), somnolence, ≥7% weight gain, overall extrapyramidal side-effects (EPSs), and akathisia, were extracted from originally published primary outcome papers. The number needed to treat to benefit (NNT) for response and remission or harm (NNH) for DAEs or other side effects relative to placebo were estimated and presented with the estimate and 95% confidence interval. Olanzapine monotherapy, olanzapine-fluoxetine combination (OFC), quetiapine-IR monotherapy, quetiapine-XR monotherapy, lurasidone monotherapy, and lurasidone adjunctive therapy were superior to placebo with NNTs for responses of 11–12, 4, 7–8, 4, 4–5, and 7, and NNTs for remission of 11–12, 4, 5–11, 7, 6–7, and 6, respectively. There was no significant difference between OFC and lamotrigine, and between aripiprazole or ziprasidone and placebo in response and remission. Olanzapine monotherapy, quetiapine-IR, quetiapine-XR, aripiprazole, and ziprasidone 120–160 mg/day had significantly increased risk for DAEs with NNHs of 24, 8–14, 9, 12, and 10, respectively. For somnolence, quetiapine-XR had the smallest NNH of 4. For ≥7% weight gain, olanzapine monotherapy and OFC had the smallest NNHs with both of 5. For akathisia, aripiprazole had the smallest NNH of 5. These findings suggest that among the FDA-approved agents including OFC, quetiapine-IR and -XR, lurasidone monotherapy and adjunctive therapy to a mood stabilizer, the differences in the NNTs for response and remission are small, but the differences in NNHs for DAEs and common side-effects are large. Therefore, the selection of an FDA-approved atypical antipsychotic for bipolar depression should be based upon safety and tolerability.Keywords
This publication has 41 references indexed in Scilit:
- Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorderNeuropsychiatric Disease and Treatment, 2013
- Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled studyBMC Psychiatry, 2013
- Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical AntipsychoticsThe Journal of Clinical Psychiatry, 2010
- Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorderInternational Journal of Neuropsychopharmacology, 2010
- Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depressionJournal of Affective Disorders, 2010
- Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and SchizophreniaJournal of Clinical Psychopharmacology, 2008
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2007
- The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measuresEuropean Neuropsychopharmacology, 2006
- Impact of Depressive Symptoms Compared With Manic Symptoms in Bipolar DisorderThe Journal of Clinical Psychiatry, 2004